company background image
BIOT logo

Biotage OM:BIOT Voorraadrapport

Laatste prijs

SEK 158.50

Marktkapitalisatie

SEK 12.7b

7D

-4.5%

1Y

29.4%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Biotage AB (publ)

OM:BIOT Voorraadrapport

Marktkapitalisatie: SEK 12.7b

BIOT Overzicht aandelen

Biotage AB (publ) levert oplossingen en producten op het gebied van het ontdekken en ontwikkelen van medicijnen, analytische tests en water- en milieutests.

Over het bedrijf

Beloningen

Trading at 60.2% below our estimate of its fair value
Earnings are forecast to grow 20.88% per year
Earnings have grown 7.3% per year over the past 5 years
Analysts in good agreement that stock price will rise by 20.3%

Risicoanalyse

Geen risico's gedetecteerd voor BIOT uit onze risicocontroles.

Biotage AB (publ) Concurrenten

AddLife

OM:ALIF B

SEK 16.6b

MedCap

OM:MCAP

SEK 8.2b

Genovis AB (publ.)

OM:GENO

SEK 1.4b

Magle Chemoswed Holding

OM:MAGLE

SEK 680.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Biotage
Historische aandelenkoersen
Huidige aandelenkoersSEK 158.50
52 Week HoogtepuntSEK 202.20
52 Week LaagSEK 108.90
Bèta0.85
11 maand verandering-13.91%
3 maanden verandering-16.54%
1 Jaar Verandering29.39%
33 jaar verandering-45.27%
5 jaar verandering26.70%
Verandering sinds IPO55.39%

Recent nieuws en updates

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Oct 26
Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Recent updates

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Oct 26
Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Jun 08
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

May 21
Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Apr 28
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Apr 17
Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Apr 08
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Apr 03
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Mar 04
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Feb 21
Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 18
Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Feb 08
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Jan 07
Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Dec 08
At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Oct 27
Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Jul 12
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Jun 08
An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

May 24
Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Mar 12
These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Feb 21
Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Jan 06
Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Dec 03
Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Oct 27
Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Oct 07
Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Biotage (STO:BIOT) Could Easily Take On More Debt

Sep 03
Biotage (STO:BIOT) Could Easily Take On More Debt

Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

Jul 10
Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Jun 25
A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

May 28
Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 23
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Rendement voor aandeelhouders

BIOTSE Life SciencesSE Markt
7D-4.5%-2.3%-2.3%
1Y29.4%38.4%21.0%

Rendement versus industrie: BIOT underperformed the Swedish Life Sciences industry which returned 38.7% over the past year.

Rendement versus markt: BIOT exceeded the Swedish Market which returned 20.7% over the past year.

Prijsvolatiliteit

Is BIOT's price volatile compared to industry and market?
BIOT volatility
BIOT Average Weekly Movement4.2%
Life Sciences Industry Average Movement7.5%
Market Average Movement5.4%
10% most volatile stocks in SE Market10.8%
10% least volatile stocks in SE Market3.2%

Stabiele aandelenkoers: BIOT has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatiliteit in de loop van de tijd: BIOT's weekly volatility (4%) has been stable over the past year.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1969675Frederic Vanderhaegenwww.biotage.com

Biotage AB (publ) levert oplossingen en producten op het gebied van het ontdekken en ontwikkelen van medicijnen, analytisch testen en water- en milieutesten. Het bedrijf biedt oplossingen voor organische en peptidensynthese; flash chromotherapie, verdamping en opwerkproducten; flash systemen; producten voor monstervoorbereiding; oplossingen voor plasmidezuivering; oplossingen voor oligo-synthese; en metaalvangers en reagentia, evenals accessoires en reserveonderdelen. Het bedrijf levert ook monstervoorbereidingsoplossingen op het gebied van klinische en bioanalyse, forensische en toxicologie, dopingcontrole bij dieren en mensen, milieu, voedsel en landbouw, evenals verbruiksartikelen en systemen; oplossingen voor proteïnezuivering, waaronder zuivering van antilichamen en gemerkte proteïnen, automatiseringssystemen en aangepaste verpakkingsdiensten, evenals PhyTip-kolommen voor ionenuitwisseling, omgekeerde fase, normale fase en gelfiltratie.

Biotage AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Biotage zich tot de beurswaarde?
BIOT fundamentele statistieken
MarktkapitalisatieSEK 12.69b
Inkomsten(TTM)SEK 257.00m
Inkomsten(TTM)SEK 2.12b

49.4x

Koers/Winstverhouding

6.0x

P/S-verhouding

Is BIOT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIOT resultatenrekening (TTM)
InkomstenSEK 2.12b
Kosten van inkomstenSEK 794.00m
BrutowinstSEK 1.32b
Overige uitgavenSEK 1.07b
InkomstenSEK 257.00m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 19, 2025

Winst per aandeel (EPS)3.21
Brutomarge62.49%
Nettowinstmarge12.14%
Schuld/Eigen Vermogen Verhouding3.9%

Hoe presteerde BIOT op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.0%

Huidig dividendrendement

50%

Uitbetalingsratio